NGM Biopharmaceuticals, Inc.
NGM · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | -$142,375 | -$162,667 | -$120,335 | -$102,487 |
| Dep. & Amort. | $2,221 | $4,035 | $6,089 | $6,555 |
| Deferred Tax | $4,977 | $0 | $3,514 | -$128 |
| Stock-Based Comp. | $28,719 | $32,383 | $26,242 | $15,651 |
| Change in WC | -$18,376 | -$20,712 | $4,208 | -$3,700 |
| Other Non-Cash | -$7,368 | $2,522 | $7,053 | $613 |
| Operating Cash Flow | -$132,202 | -$144,439 | -$73,229 | -$83,496 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$1,252 | -$1,858 | -$1,684 | -$1,879 |
| Net Acquisitions | $0 | -$16,180 | $69,966 | $49,119 |
| Inv. Purchases | -$105,431 | -$272,857 | -$293,466 | -$177,655 |
| Inv. Sales/Matur. | $220,970 | $289,037 | $223,500 | $128,536 |
| Other Inv. Act. | $0 | $16,180 | -$69,966 | -$49,119 |
| Investing Cash Flow | $114,287 | $14,322 | -$71,650 | -$50,998 |
| Financing Activities | – | – | – | – |
| Debt Repay. | $0 | $0 | $0 | $0 |
| Stock Issued | $1,775 | $2,984 | $0 | $0 |
| Stock Repurch. | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Fin. Act. | $1,775 | $54,233 | $149,657 | $35,538 |
| Financing Cash Flow | $1,775 | $54,233 | $149,657 | $35,538 |
| Forex Effect | $1,499 | $0 | $0 | $0 |
| Net Chg. in Cash | -$14,641 | -$75,884 | $4,778 | -$98,956 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $73,456 | $153,294 | $148,516 | $247,472 |
| End Cash | $58,815 | $77,410 | $153,294 | $148,516 |
| Free Cash Flow | -$133,454 | -$146,297 | -$74,913 | -$85,375 |